{"id":"W2787480145","doi":"10.1016/j.jacl.2018.01.013","title":"Alirocumab in high-risk patients: Observations from the open-label expanded use program","year":2018,"lang":"en","type":"article","venue":"Journal of clinical lipidology","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sanofi (Canada)","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Alirocumab; Medicine; Familial hypercholesterolemia; PCSK9; Statin; Internal medicine; Evolocumab; Cholesterol; Lipoprotein; LDL receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003785079,0.0001285192,0.0009873935,0.00005511794,0.000103768,0.0000504041,0.0004255807,0.0002679031,0.00008496382],"category_scores_gemma":[0.008763457,0.00007290799,0.0002621547,0.0002390179,0.0002709937,0.000256094,0.0001710481,0.000967891,0.00002150651],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004677272,"about_ca_system_score_gemma":0.0004293001,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001731417,"about_ca_topic_score_gemma":0.0008461331,"domain_scores_codex":[0.9961137,0.001172614,0.001812017,0.000232397,0.0004029115,0.0002663655],"domain_scores_gemma":[0.9959587,0.001563708,0.0009419798,0.0005979225,0.0007150362,0.0002226713],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001307136,0.002088114,0.8031752,0.000004971771,0.0003065698,0.000008703701,0.00009594621,4.888931e-7,0.00000479143,0.0001772769,0.009088792,0.1837421],"study_design_scores_gemma":[0.0154987,0.005189414,0.8762681,0.00009945806,0.0002264448,0.00001976386,0.00004564339,0.00002761311,0.000005543061,0.001095947,0.1014548,0.000068575],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990562,0.0001434163,0.0001875332,0.004769229,0.003437286,0.0007922109,0.00001584272,0.00001175136,0.00008074777],"genre_scores_gemma":[0.9630654,0.0007551867,0.0190751,0.006405721,0.0105397,0.00002642354,0.00002270726,0.00002318035,0.00008657808],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1836735,"threshold_uncertainty_score":0.9995862,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2118351454886508,"score_gpt":0.4463498752314411,"score_spread":0.2345147297427903,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}